FIELD: biotechnology; medicine.
SUBSTANCE: present invention relates to biotechnology and can be used in medicine. Invention discloses conjugates of an anti-CLDN18.2 antibody with a drug, specifically a cytotoxic or cytostatic agent.
EFFECT: invention can be used for treating or preventing oncological diseases associated with cells expressing CLDN18.2, including stomach cancer, oesophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, liver cancer, head and neck cancer, gall bladder cancer and their metastases.
31 cl, 9 ex, 11 tbl, 26 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION THERAPY USING ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER TREATMENT | 2014 |
|
RU2792932C2 |
| THERAPY FOR TREATING CANCER, INCLUDING ANTIBODIES AGAINST CLAUDIN 18.2 | 2014 |
|
RU2832015C2 |
| METHODS AND COMPOSITIONS FOR PREDICTION OF THERAPEUTIC EFFICIENCY OF TREATMENT OF ONCOLOGICAL DISEASES AND PREDICTION OF ONCOLOGICAL DISEASES | 2016 |
|
RU2785291C2 |
| NOVEL ANTI-CLDN18.2 ANTIBODIES | 2020 |
|
RU2830887C2 |
| ANTI-CLDN ANTIBODY, ITS PHARMACEUTICAL COMPOSITION AND A METHOD OF ITS DETECTION | 2020 |
|
RU2801315C2 |
| AGENTS FOR THE TREATMENT OF CLAUDINE-EXPRESSING CANCER DISEASES | 2013 |
|
RU2798990C2 |
| ANTIBODY AGAINST CLAUDIN 18A2 AND ITS USE | 2020 |
|
RU2811431C2 |
| BISPECIFIC TRIVALENT ANTIBODIES BINDING TO CLAUDIN 6 OR CLAUDIN 18.2 AND CD3 FOR THE TREATMENT OF ONCOLOGICAL DISEASES WITH CLAUDIN EXPRESSION | 2017 |
|
RU2798988C2 |
| ANTI-CLAUDIN ANTIBODIES AND USE THEREOF | 2019 |
|
RU2815926C2 |
| ANTI-CLDN-18.2 ANTIBODY AND USE THEREOF | 2021 |
|
RU2829997C1 |
